Charles Chavkin

Affiliations: 
University of Washington, Seattle, Seattle, WA 
Area:
Opioid receptors, potassium channels
Google:
"Charles Chavkin"
Mean distance: 13.02 (cluster 40)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Heymann G, Jo YS, Reichard KL, et al. (2019) Synergy of Distinct Dopamine Projection Populations in Behavioral Reinforcement. Neuron
Schattauer SS, Bedini A, Summers F, et al. (2019) ROS generation is stimulated by kappa opioid receptor activation through phosphorylated c-Jun-N-terminal kinase and inhibited by p38 MAPK activation. The Journal of Biological Chemistry
Chavkin C, Cohen JH, Land BB. (2019) Repeated Administration of Norbinaltorphimine Produces Cumulative Kappa Opioid Receptor Inactivation. Frontiers in Pharmacology. 10: 88
Abraham AD, Schattauer SS, Reichard KL, et al. (2018) Estrogen regulation of GRK2 inactivates kappa opioid receptor signaling mediating analgesia, but not aversion. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience
Schattauer SS, Land BB, Reichard KL, et al. (2017) Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase. Nature Communications. 8: 743
Abraham AD, Fontaine HM, Song AJ, et al. (2017) Kappa Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Schattauer SS, Kuhar JR, Song A, et al. (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cellular Signalling
Chavkin C, Koob GF. (2016) Dynorphin, Dysphoria, and Dependence: the Stress of Addiction. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 41: 373-4
Ehrich JM, Messinger DI, Knakal CR, et al. (2015) Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 12917-31
Chavkin C, Martinez D. (2015) Kappa Antagonist JDTic in Phase 1 Clinical Trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 2057-8
See more...